HDP1 Stock Chart & Stats
CHF71.34
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF71.34
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF59.12 - CHF74.77
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
CHF9.34B
Enterprise ValueCHF11.46K
Total Cash (Recent Filing)CHF1.60B
Total Debt (Recent Filing)CHF864.07M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Nov 30, 2026EPS Estimate
-1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio28.34
Price to Book (P/B)9.90
Price to Sales (P/S)5.56
P/FCF Ratio29.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF93.02Price Target Upside30.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.92
Revenue Forecast (FY)CHF373.03M
Bulls Say, Bears Say
Bulls Say
Phase III EfficacyPivotal trials achieving deep, durable and consistent triglyceride reductions materially de-risk plozasiran’s clinical profile. The associated reduction in acute pancreatitis events supports a meaningful medical benefit, strengthening the foundation for regulatory approval and future commercial adoption.
RNAi Pipeline BreadthARO-DIMER-PA provides clinical evidence that Arrowhead’s RNAi platform can silence multiple targets in one therapy and generate broad lipid effects. Progress beyond the lead program diversifies the development pipeline and creates additional opportunities across cardiometabolic disease.
Partnerships And LiquidityA substantial cash and investment balance gives Arrowhead capacity to fund clinical development and commercialization while continuing to advance a broad pipeline. Collaboration income from major pharmaceutical partners further supports the platform and can reduce reliance on immediate product sales.
Bears Say
Persistent UnprofitabilityDeep operating and net losses show that Arrowhead has not yet converted its growing revenue base into sustainable earnings. Continued investment in research and commercialization may preserve long-term opportunities, but ongoing losses increase execution pressure and could require additional financing.
Negative And Volatile Cash FlowNegative trailing cash generation indicates that current operations do not fully fund development and commercialization spending. Although cash flow improved from the 2024 burn and was positive in 2025, the reversal highlights uneven cash conversion and the risk of funding needs if spending remains elevated.
Early Commercial MonetizationREDEMPLO prescription growth is encouraging, but product revenue remains small relative to the company’s operating scale and collaboration income. At the same time, the planned $215 million voucher payment creates a substantial near-term cash commitment before the accelerated regulatory benefit can translate into broader sales.
Arrowhead Pharmaceuticals News
HDP1 FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was CHF59.12 and its highest was CHF74.77 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is CHF9.34B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is Nov 30, 2026 which is in 75 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Aug 04, 2026. The company reported -CHF1.101 earnings per share for the quarter, missing the consensus estimate of -CHF1.033 by -CHF0.067.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -1.26.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Currently, no data Available
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -CHF1.101 in its last earnings report, missing expectations of -CHF1.033. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:HDP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arrowhead Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF93.02 (30.39% Upside)
CHF93.02 (30.39% Upside)
Blogger Sentiment
Bullish
CH:HDP1 Sentiment 75%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth CHF968.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
146.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
52.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
HDP1 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was decidedly positive on clinical and strategic fronts: landmark Phase III SHASTA-3/4 results (deep TG reductions and major reductions in acute pancreatitis), broad regulatory approvals, accelerating commercial traction in FCS, strong partnership revenue and a robust pipeline with multiple near-term data catalysts. Offsetting items include increased net losses and higher operating spend as Arrowhead scales R&D and commercial infrastructure, a sizable near-term cash payment for a priority review voucher ($215M), and the fact that commercial product revenues remain small today. Overall, management portrayed the financial investments as deliberate and tied to significant near-term derisking and value-creation events.View all CH:HDP1 earnings summariesHDP1 Stock 12 Month Forecast
Average Price Target
CHF93.02
▲(30.39% Upside)